Day One Biopharmaceuticals, Inc. (DAWN)

$21.45

-0.09 (-0.42%)
Rating:
Recommendation:
-
Symbol DAWN
Price $21.45
Beta 0.000
Volume Avg. 0.54M
Market Cap 1.578B
Shares () -
52 Week Range 5.44-28.35
1y Target Est -
DCF Unlevered DAWN DCF ->
DCF Levered DAWN LDCF ->
ROE -69.22% Strong Sell
ROA -58.66% Strong Sell
Operating Margin -
Debt / Equity 5.17% Neutral
P/E 3.90 Buy
P/B 4.20 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest DAWN news


Healthcare
Biotechnology
NASDAQ Global Select

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.